82 related articles for article (PubMed ID: 22559244)
1. Endothelin-1 and adrenomedullin plasma levels after exposure to fludrocortisone, dexamethasone, and spironolactone.
Vogt S; Winkler E; Hermsen D; Schott M; Schinner S; Scherbaum WA; Willenberg HS
Clin Exp Hypertens; 2012; 34(8):582-7. PubMed ID: 22559244
[TBL] [Abstract][Full Text] [Related]
2. Volume-pressure relationships during development of mineralocorticoid hypertension in man.
Wenting GH; Man in 't Veld AJ; Verhoeven RP; Derkx FH; Schalekamp DH
Circ Res; 1977 May; 40(5 Suppl 1):I163-70. PubMed ID: 858175
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.
Hu W; Zhou PH; Zhang XB; Xu CG; Wang W
Endocrine; 2015 Mar; 48(2):661-8. PubMed ID: 25027294
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
5. [Does spironolactone use at arterial hypertension therapy protect endothelium also in smoking patients?].
Kara-Perz H; Kosicka T; Perz S
Przegl Lek; 2009; 66(10):571-3. PubMed ID: 20301883
[TBL] [Abstract][Full Text] [Related]
6. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
7. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
[TBL] [Abstract][Full Text] [Related]
9. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
10. [Rectal electrical potential difference and plasma aldosterone in hyperaldosteronism and low-, normal- and high-renin hypertension].
Skrabal F; Mauser R
Wien Klin Wochenschr; 1976 Dec; 88(23):777-81. PubMed ID: 1014711
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.
Douma S; Petidis K; Doumas M; Papaefthimiou P; Triantafyllou A; Kartali N; Papadopoulos N; Vogiatzis K; Zamboulis C
Lancet; 2008 Jun; 371(9628):1921-6. PubMed ID: 18539224
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
Mahmud A; Feely J
Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
[TBL] [Abstract][Full Text] [Related]
13. Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
Ge Y; Huang Y; Kohan DE
Can J Physiol Pharmacol; 2008 Jun; 86(6):329-36. PubMed ID: 18516095
[TBL] [Abstract][Full Text] [Related]
14. [High circulating levels of adrenomedullin and endothelin-1 in obesity associated with arterial hypertension].
Letizia C; Celi M; Cerci S; Scuro L; Delfini E; Subioli S; Caliumi C; D'Erasmo E
Ital Heart J Suppl; 2001 Sep; 2(9):1011-5. PubMed ID: 11675821
[TBL] [Abstract][Full Text] [Related]
15. Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension.
Cuzzola F; Mallamaci F; Tripepi G; Parlongo S; Cutrupi S; Cataliotti A; Stancanelli B; Malatino L; Bellanuova I; Ferri C; Galletti F; Filigheddu F; Glorioso N; Strazzullo P; Zoccali C
Am J Hypertens; 2001 Mar; 14(3):224-30. PubMed ID: 11281233
[TBL] [Abstract][Full Text] [Related]
16. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
Mahmud A; Mahgoub M; Hall M; Feely J
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
[TBL] [Abstract][Full Text] [Related]
17. [Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension].
Naudzhunas A; Bagdonas G; Yankauskene L; Kazanavichus G
Ter Arkh; 2006; 78(2):61-4. PubMed ID: 16613101
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone for all hypertensive patients?
Rosendorff C
J Hypertens; 2010 Jan; 28(1):13-4. PubMed ID: 20016304
[No Abstract] [Full Text] [Related]
19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
20. [Hypertension treatable with glucocorticoids: report of a case].
Montero J; Fardella C; Mosso L
Rev Med Chil; 1997 Nov; 125(11):1361-5. PubMed ID: 9609059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
